MSL3

Across TCGA pan-cancer cohorts, MSL3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSL3 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MSL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where MSL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.384	0.833	.015	13	view →
HNSC	DFS	Tertile	All	1.000	0.505	.038	6	view →
PDAC	OS	Median	II,III,IV	0.678	0.898	.044	3	view →
CCRCC	OS	Median	All	0.959	0.742	.023	1	view →
LSCC	DFS	Median	III,IV	0.990	0.621	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSL3–LUAD (DFS)

Open the LUAD breakdown →